Freenome Reports Positive Results for SimpleScreen CRC Test
Health
Business Update
Merger:
Jul 21, 2026
Industry:
MEDICAL LABORATORIES
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
Freenome Reports Successful Clinical Validation for Updated SimpleScreen CRC Blood Test
Brisbane, CA - Freenome Holdings, Inc. has announced favorable results from its pivotal clinical validation study for its updated SimpleScreen CRC blood-based colorectal cancer screening test. The study successfully met all primary and secondary endpoints, demonstrating significant performance improvements, particularly in the detection of advanced precancerous lesions (APLs).
Key Highlights:
... Read on — Members only
About Freenome Holdings, Inc.
Freenome is an early cancer detection company developing blood-based tests to detect cancer when it is most treatable. The company recognizes that no single technology can identify every cancer due to the disease’s inherent heterogeneity. Freenome’s approach combines a multiomics platform that analyzes multiple signals in the blood with artificial intelligence and machine learning to tune into cancer’s subtlest clues, even at the earliest stages of the disease.
